A Phase 2 randomized, double-blind, placebo-controlled study to investigate efficacy, safety, immunogenicity, and pharmacokinetics, of GSK3862995B in participants with bronchiectasis
Фаза 2 – изследване на ефективността и дозировката
Заболявания:
Bronchiectasis
Спонсор: GSK PLC
Налично на:
БГ
Обобщение
Trial status: Authorised
1. Annualized rate of exacerbationsa, 2. Time to first exacerbation, 3. Annualized rate of severe exacerbations
What is the percentage reduction in annualized exacerbation rate on GSK3862995B versus placebo, in adult patients with bronchiectasis and recurrent exacerbations or uncontrolled symptoms assuming no study treatment discontinuation occurred, change in maintenance SOC or use of prohibited medications.
Описание
1. Annualized rate of exacerbationsa, 2. Time to first exacerbation, 3. Annualized rate of severe exacerbations
Кой може да участва
Age group: 65+ years, 18-64 years
Gender: Female, Male
Target enrollment: 207 participants
БГ
EN